⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
HOWL News
Werewolf Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
HOWL
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
globenewswire.com
HOWL
Form 8-K
sec.gov
HOWL
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
globenewswire.com
HOWL
Werewolf Therapeutics Announces Pipeline and Business Updates
globenewswire.com
HOWL
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
globenewswire.com
HOWL
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
globenewswire.com
HOWL
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
globenewswire.com
HOWL
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
globenewswire.com
HOWL